Rhelion Life Sciences' Wholly Owned Subsidiary Filament Health Ships PEX010 to the University of Calgary for Phase 2 Trial of Psilocybin-Assisted Therapy for PTSD in Survivors of Intimate Partner ViolenceNewsfile Corp · Sep 29, 2026
Rhelion Life Sciences' Wholly Owned Subsidiary Filament Health Expands Supply Agreement with the University of Chieti-Pescara for PEX010 in the TEMPO Clinical Trial of Psilocybin for Treatment-Resistant Depression in ItalyNewsfile Corp · Sep 25, 2026
Rhelion Life Sciences' Wholly Owned Subsidiary Filament Health Delivers PEX010 to Bruyere Health Research Institute's Phase 3 Trial of Microdose Psilocybin in Palliative CareNewsfile Corp · Sep 21, 2026
Rhelion Life Sciences' Wholly Owned Subsidiary Filament Health Signs Supply and Licensing Agreement with the Centre for Human Drug Research for PEX010 in a Study of Low and Medium Dose PsilocybinNewsfile Corp · Sep 17, 2026
Rhelion Life Sciences' Wholly Owned Subsidiary Filament Health Completes Shipment of PEX010 to Australia for University of Melbourne Trial of Psilocybin-Assisted Physiotherapy in Functional Neurological DisorderNewsfile Corp · Sep 8, 2026
Rhelion Life Sciences Confirms Further Delivery of Filament Health's PEX010 to Germany's First Psilocybin Compassionate Use ProgramNewsfile Corp · Sep 3, 2026PEX is the third launch in the Global Private Equity Segment and is a market-cap-selected and -weighted fund, thus offering plain vanilla exposure to investors. The underlying index tracks 30 qualifying listed private equity companies which were screened based on, among other things, greater relative trading volume. Generally, the fund will invest at least 80% of its total assets in component securities of the index, and will primarily invest in common stocks of domestic and foreign companies (including in large part BDCs for US-domiciled companies) of any size.